全文获取类型
收费全文 | 15654篇 |
免费 | 1156篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 189篇 |
儿科学 | 482篇 |
妇产科学 | 324篇 |
基础医学 | 2122篇 |
口腔科学 | 201篇 |
临床医学 | 2010篇 |
内科学 | 3229篇 |
皮肤病学 | 257篇 |
神经病学 | 1655篇 |
特种医学 | 412篇 |
外国民族医学 | 2篇 |
外科学 | 1711篇 |
综合类 | 171篇 |
一般理论 | 12篇 |
预防医学 | 1795篇 |
眼科学 | 360篇 |
药学 | 993篇 |
中国医学 | 28篇 |
肿瘤学 | 882篇 |
出版年
2023年 | 93篇 |
2022年 | 62篇 |
2021年 | 376篇 |
2020年 | 216篇 |
2019年 | 358篇 |
2018年 | 378篇 |
2017年 | 319篇 |
2016年 | 335篇 |
2015年 | 363篇 |
2014年 | 555篇 |
2013年 | 751篇 |
2012年 | 1196篇 |
2011年 | 1236篇 |
2010年 | 611篇 |
2009年 | 600篇 |
2008年 | 1019篇 |
2007年 | 1036篇 |
2006年 | 1016篇 |
2005年 | 1018篇 |
2004年 | 1003篇 |
2003年 | 916篇 |
2002年 | 812篇 |
2001年 | 165篇 |
2000年 | 132篇 |
1999年 | 167篇 |
1998年 | 133篇 |
1997年 | 98篇 |
1996年 | 111篇 |
1995年 | 114篇 |
1994年 | 92篇 |
1993年 | 91篇 |
1992年 | 94篇 |
1991年 | 113篇 |
1990年 | 87篇 |
1989年 | 77篇 |
1988年 | 81篇 |
1987年 | 92篇 |
1986年 | 95篇 |
1985年 | 79篇 |
1984年 | 73篇 |
1983年 | 52篇 |
1982年 | 48篇 |
1981年 | 52篇 |
1980年 | 51篇 |
1979年 | 45篇 |
1978年 | 33篇 |
1977年 | 33篇 |
1976年 | 40篇 |
1975年 | 41篇 |
1972年 | 33篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Sanne C. F. A. Huijberts Robin M. J. M. van Geel Emilie M. J. van Brummelen Frans L. Opdam Serena Marchetti Neeltje Steeghs Saskia Pulleman Bas Thijssen Hilde Rosing Kim Monkhorst Alwin D. R. Huitema Jos H. Beijnen Ren Bernards Jan H. M. Schellens 《Cancer chemotherapy and pharmacology》2020,85(5):917-930
KRAS oncogene mutations cause sustained signaling through the MAPK pathway. Concurrent inhibition of MEK, EGFR, and HER2 resulted in complete inhibition of tumor growth in KRAS-mutant (KRASm) and PIK3CA wild-type tumors, in vitro and in vivo. In this phase I study, patients with advanced KRASm and PIK3CA wild-type colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and pancreatic cancer, were treated with combined lapatinib and trametinib to assess the recommended phase 2 regimen (RP2R). Patients received escalating doses of continuous or intermittent once daily (QD) orally administered lapatinib and trametinib, starting at 750 mg and 1 mg continuously, respectively. Thirty-four patients (16 CRC, 15 NSCLC, three pancreatic cancers) were enrolled across six dose levels and eight patients experienced dose-limiting toxicities, including grade 3 diarrhea (n = 2), rash (n = 2), nausea (n = 1), multiple grade 2 toxicities (n = 1), and aspartate aminotransferase elevation (n = 1), resulting in the inability to receive 75% of planned doses (n = 2) or treatment delay (n = 2). The RP2R with continuous dosing was 750 mg lapatinib QD plus 1 mg trametinib QD and with intermittent dosing 750 mg lapatinib QD and trametinib 1.5 mg QD 5 days on/2 days off. Regression of target lesions was seen in 6 of the 24 patients evaluable for response, with one confirmed partial response in NSCLC. Pharmacokinetic results were as expected. Lapatinib and trametinib could be combined in an intermittent dosing schedule in patients with manageable toxicity. Preliminary signs of anti-tumor activity in NSCLC have been observed and pharmacodynamic target engagement was demonstrated. 相似文献
2.
3.
Thomas Asendorf Robin Henderson Heinz Schmidli Tim Friede 《Statistics in medicine》2019,38(9):1503-1528
In some diseases, such as multiple sclerosis, lesion counts obtained from magnetic resonance imaging (MRI) are used as markers of disease progression. This leads to longitudinal, and typically overdispersed, count data outcomes in clinical trials. Models for such data invariably include a number of nuisance parameters, which can be difficult to specify at the planning stage, leading to considerable uncertainty in sample size specification. Consequently, blinded sample size re-estimation procedures are used, allowing for an adjustment of the sample size within an ongoing trial by estimating relevant nuisance parameters at an interim point, without compromising trial integrity. To date, the methods available for re-estimation have required an assumption that the mean count is time-constant within patients. We propose a new modeling approach that maintains the advantages of established procedures but allows for general underlying and treatment-specific time trends in the mean response. A simulation study is conducted to assess the effectiveness of blinded sample size re-estimation methods over fixed designs. Sample sizes attained through blinded sample size re-estimation procedures are shown to maintain the desired study power without inflating the Type I error rate and the procedure is demonstrated on MRI data from a recent study in multiple sclerosis. 相似文献
4.
5.
6.
7.
Ashley Sharp Berit Muller-Pebody Andre Charlett Bharat Patel Rebecca Gorton Jonathan Lambourne Martina Cummins Adela Alcolea-Medina Mark Wilks Robin Smith Damien Mack Susan Hopkins Andrew Dodgson Phillipa Burns Nelun Perera Felicia Lim Gopal Rao Priya Khanna Elizabeth Johnson Andrew Borman Silke Schelenz Rebecca Guy Joanna Conneely Rohini J Manuel Colin S Brown 《Euro surveillance : bulletin européen sur les maladies transmissibles = European communicable disease bulletin》2021,26(8)
Background Candida auris is an emerging multidrug-resistant fungal pathogen associated with bloodstream, wound and other infections, especially in critically ill patients. C. auris carriage is persistent and is difficult to eradicate from the hospital environment.AimWe aimed to pilot admission screening for C. auris in intensive care units (ICUs) in England to estimate prevalence in the ICU population and to inform public health guidance.MethodsBetween May 2017 and April 2018, we screened admissions to eight adult ICUs in hospitals with no previous cases of C. auris, in three major cities. Swabs were taken from the nose, throat, axilla, groin, perineum, rectum and catheter urine, then cultured and identified using matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS). Patient records were linked to routine ICU data to describe and compare the demographic and health indicators of the screened cohort with a national cohort of ICU patients admitted between 2016 and 2017.ResultsAll C. auris screens for 921 adults from 998 admissions were negative. The upper confidence limit of the pooled prevalence across all sites was 0.4%. Comparison of the screened cohort with the national cohort showed it was broadly similar to the national cohort with respect to demographics and co-morbidities.ConclusionThese findings imply that C. auris colonisation among patients admitted to ICUs in England is currently rare. We would not currently recommend widespread screening for C. auris in ICUs in England. Hospitals should continue to screen high-risk individuals based on local risk assessment. 相似文献
8.
9.
10.
Robin W.M. Vernooij Inge van Oort Theo M. de Reijke Katja K.H. Aben 《Journal of Geriatric Oncology》2019,10(2):252-258